Apparently, up to 81% of the EMA staff currently based in London would be willing to move to Amsterdam (
link) which is good news for both the EMA and its' staff. Of course, it's bad news for the MHRA who is going to need some regulators sharpish if we leave the EMA (and its' cost and ECJ arbitration)
Of course we have some staff already but EMA has had overview on drugs for the following conditions;
- human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS);
- cancer;
- diabetes;
- neurodegenerative diseases;
- auto-immune and other immune dysfunctions;
- viral diseases.
Plus
- medicines derived from biotechnology processes, such as genetic engineering;
- advanced-therapy medicines, such as gene-therapy, somatic cell-therapy or tissue-engineered medicines;
- orphan medicines (medicines for rare diseases);
- veterinary medicines for use as growth or yield enhancers.
But hey, as Michael Gove said '..people of this country have had enough of experts with organisations from acronyms'